<DOC>
	<DOCNO>NCT00055679</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know combination chemotherapy regimen effective treat early breast cancer . PURPOSE : Randomized phase III trial determine effectiveness different regimen combination chemotherapy treat woman stage I breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Women With Stage I Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy 4 v 6 course adjuvant fluorouracil , epirubicin , cyclophosphamide , term 5-year survival , woman stage I breast cancer . - Compare toxicity regimens patient . - Determine correlation length survival biological factor patient treat regimen . - Determine biological factor significant prognosis prediction survival patient treat regimen . - Determine overall survival patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive fluorouracil IV , epirubicin IV , cyclophosphamide IV day 1 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive regimen arm I 4 course . After completion chemotherapy , patient undergo radiotherapy 5 day week 6 week . Patients estrogen progesterone receptor positive also receive oral tamoxifen daily 5 year , begin completion chemotherapy . Patients follow every 6 month 5 year . PROJECTED ACCRUAL : A total 1,512 patient ( 756 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonmetastatic , unilateral adenocarcinoma breast Stage I No clinically radiologically suspicious metastasis No positive sentinel lymph node immunohistochemistry tumor le 2 cm No clinically proven positive axillary lymph node Tumor cell find immunohistochemistry allow No clinically radiologically contralateral suspicious lesion No deeply adherent disease No cutaneous invasion No inflammatory disease Complete surgical resection within past 42 day At least 8 lymph node remove Tumor least 1 cm residual disease Presenting least 1 follow factor poor prognosis : Tumor great 2 cm Hormone receptor negative tumor Grade II III 35 year old Hormone receptor status : Positive negative PATIENT CHARACTERISTICS : Age 18 65 Sex Female Menopausal status Not specify Performance status WHO 01 Life expectancy Not specify Hematopoietic WBC least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.25 time upper limit normal ( ULN ) AST ALT great 1.25 time ULN Alkaline phosphatase great 2.5 time ULN No chronic hepatitis B No active hepatitis C Renal Creatinine great 1.25 time ULN Pulmonary FEV normal Other Not pregnant nursing HIV negative No prior breast cancer malignancy No familial , social , geographical reason would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy No prior anticancer hormone therapy Radiotherapy No prior radiotherapy Surgery See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage I breast cancer</keyword>
</DOC>